Advantages and disadvantages of production quality of Fufang Danshen Prescription based on high-quality Chinese patent medicine evaluation criteria.
10.19540/j.cnki.cjcmm.20211118.301
- Author:
An-Yi ZHAO
1
;
Yan-Ping LIU
1
;
Sha CHEN
1
;
Cong GUO
1
;
Yu-Zhen LIU
2
;
Zhi-Guang WANG
2
;
Yan LIU
1
;
An LIU
1
Author Information
1. Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences Beijing 100700, China.
2. All-China Federation of Industry and Commerce Medical and Pharmaceutical Commercial Association Beijing 100101, China.
- Publication Type:Journal Article
- Keywords:
Chinese patent medicine;
Fufang Danshen Prescription;
high-quality evaluation;
post-marketing research;
production process;
quality control;
raw materials selection
- MeSH:
China;
Drugs, Chinese Herbal/analysis*;
Humans;
Medicine, Chinese Traditional;
Nonprescription Drugs;
Prescriptions
- From:
China Journal of Chinese Materia Medica
2022;47(17):4814-4822
- CountryChina
- Language:Chinese
-
Abstract:
The big brand of Chinese patent medicine, Fufang Danshen Prescription(FDP), effective in promoting blood circulation, resolving blood stasis, regulating qi, and relieving pain, is wide in clinical application and diverse in dosage forms and products, but its quality and price are uneven, which causes problems for doctors and patients. To clarify the key links and weakness of quality control leading to the quality difference of FDP products, the present study carried out a comprehensive evaluation of the whole production cycle of FDP based on the "high-quality Chinese patent medicine evaluation criteria" and analyzed the advantages and disadvantages of production and quality of different FDP products according to scores. The results showed that the scores of various products in the "raw materials selection" varied greatly. The highest score(S1) and the lowest score(S2) differed by more than 3 times, indicating that different manufacturers had inconsistent requirements for the selection of raw materials, leading to fundamental differences in the quality of raw materials. The scores in the "production process" varied slightly, with an average score of 66.8%. The manufacturer S8 obtained the highest score(84.0%), which indicated the emergence of intelligent manufacturing production. The scores(with the average score of 44.0%) in the "quality control" were lower than those of the previous two items, which was attributed to the fact that most FDP products only met the "qualified" benchmark required by the 2020 edition of Chinese Pharmacopoeia, and their consistency and high quality were both uncontrollable. The scores in the "post-marketing research" were the lowest(with an average score of 28.5%), and most manufacturers were scored 0, which reflected little attention paid. Only a few brand manufacturers were scored acceptably and they were willing to carry out relevant research on post-marketing evaluation. The evaluation results demonstrated the key links and weakness leading to the production and quality differences of FDP from different manufacturers. It is expected to improve the quality of FDP, promote the formation of the "high quality and good price" mechanism, and provide information for the centralized procurement of governments.
